[go: up one dir, main page]

MX2020014000A - Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. - Google Patents

Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.

Info

Publication number
MX2020014000A
MX2020014000A MX2020014000A MX2020014000A MX2020014000A MX 2020014000 A MX2020014000 A MX 2020014000A MX 2020014000 A MX2020014000 A MX 2020014000A MX 2020014000 A MX2020014000 A MX 2020014000A MX 2020014000 A MX2020014000 A MX 2020014000A
Authority
MX
Mexico
Prior art keywords
producing
methods
formulations containing
film formulations
containing dexmedetomidine
Prior art date
Application number
MX2020014000A
Other languages
English (en)
Inventor
Frank Yocca
Vasukumar Kakumanu
Chetan Dalpatbhai Lathia
David Christian Hanley
Scott David Barnhart
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MX2020014000A publication Critical patent/MX2020014000A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describe una lámina autosuficiente y soluble que contiene dexmedetomidina o una sal farmacéuticamente aceptable de esta. La lámina se administra oralmente para tratar varias afecciones, particularmente la agitación, a través de una administración por vía transmucosa del agente activo.
MX2020014000A 2018-06-27 2019-06-26 Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. MX2020014000A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862690407P 2018-06-27 2018-06-27
US201862693726P 2018-07-03 2018-07-03
US201862767422P 2018-11-14 2018-11-14
US201962787649P 2019-01-02 2019-01-02
US201962798842P 2019-01-30 2019-01-30
US201962849747P 2019-05-17 2019-05-17
PCT/US2019/039268 WO2020006092A1 (en) 2018-06-27 2019-06-26 Film formulations containing dexmedetomidine and methods of producing them

Publications (1)

Publication Number Publication Date
MX2020014000A true MX2020014000A (es) 2021-06-15

Family

ID=68987261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014000A MX2020014000A (es) 2018-06-27 2019-06-26 Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.

Country Status (15)

Country Link
US (9) US10792246B2 (es)
EP (2) EP3813802B1 (es)
JP (2) JP7488201B2 (es)
KR (1) KR102824967B1 (es)
CN (5) CN112888431B (es)
AU (2) AU2019295699A1 (es)
BR (1) BR112020026672A2 (es)
CA (1) CA3103431A1 (es)
ES (1) ES3004544T3 (es)
IL (1) IL279713B2 (es)
MX (1) MX2020014000A (es)
PL (1) PL3813802T3 (es)
PT (1) PT3813802T (es)
SG (1) SG11202012772XA (es)
WO (1) WO2020006092A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021138564A1 (en) * 2019-12-31 2021-07-08 Cure Pharmaceutical Holding Corp. Oral dissolvable film and method of manufacturing and using the same
TW202241416A (zh) * 2021-01-04 2022-11-01 美商百歐克斯賽爾治療公司 右美托咪啶（ｄｅｘｍｅｄｅｔｏｍｉｄｉｎｅ）治療方案
KR20230159515A (ko) 2021-03-19 2023-11-21 오리온 코포레이션 타시피미딘 제형 및 이의 용도
JP2024524434A (ja) * 2021-07-02 2024-07-05 バイオエクセル セラピューティクス，インコーポレイテッド うつ状態を処置するための方法
IL318007A (en) 2022-07-27 2025-02-01 Universit?T Z?Rich Dexmedetocidin for the treatment of sleep disorders
TW202421126A (zh) * 2022-09-11 2024-06-01 美商百歐克斯賽爾治療公司 治療在社區環境中躁動的方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025043236A1 (en) * 2023-08-24 2025-02-27 Joseph Fuisz Edible oral films, compositions, method of manufacture and packaging systems
WO2025147530A1 (en) * 2024-01-05 2025-07-10 Taho Pharmaceuticals Ltd. Naloxone buccal film product and uses thereof
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用
CN119139275B (zh) * 2024-11-05 2025-08-22 中国人民解放军军事科学院军事医学研究院 一种盐酸右美托咪定口溶膜及其制备方法和其应用

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
US4839170A (en) 1985-10-01 1989-06-13 Survival Technology, Inc. Protein absorption enhancing agents
US4760093A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4767789A (en) 1986-10-21 1988-08-30 American Home Products Corporation (Del.) Spray dried acetaminophen
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
AU688283B2 (en) 1992-09-29 1998-03-12 Novartis Ag Pulmonary delivery of active fragments of parathyroid hormone
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
DE69429119T2 (de) 1993-07-09 2002-07-18 R.P. Scherer Corp., Troy Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5508367A (en) 1993-11-29 1996-04-16 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5395907A (en) 1993-11-29 1995-03-07 Adhesive Research, Inc. Water-soluble pressure sensitive adhesive
ES2128037T3 (es) 1993-11-29 1999-05-01 Adhesives Res Inc Adhesivo sensible a la presion soluble en agua.
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US5726250A (en) 1994-07-11 1998-03-10 Adhesives Research, Inc. Covalently crosslinked water-absorbent graft copolymer
US5731387A (en) 1994-07-11 1998-03-24 Adhesives Research, Inc. Ionically-crosslinked water-absorbent graft copolymer
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US6726928B2 (en) 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5700873A (en) 1995-03-07 1997-12-23 Adhesives Research, Inc. Method of preparation of water-soluble copolymer
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9616672D0 (en) 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
ATE421318T1 (de) 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
JP2001513124A (ja) 1997-02-21 2001-08-28 アドヒーシブズ リサーチ，インコーポレイテッド 感圧接着性薬剤透皮投与複合材とそれに使用する感圧接着性薬剤
US6239228B1 (en) 1997-02-21 2001-05-29 Adhesives Research, Inc. Pressure sensitive adhesive containing macromer having repeat hydrophilic moieties
US5951999A (en) 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
DE69834255T2 (de) 1997-07-25 2006-09-28 Alpex Pharma S.A. Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
DE69923326T2 (de) 1998-03-09 2006-01-05 Cima Labs Inc., Eden Prairie Vorrichtung zum handhaben und verpacken von spröden tabletten
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
US7565905B2 (en) 1998-06-03 2009-07-28 Scott Laboratories, Inc. Apparatuses and methods for automatically assessing and monitoring a patient's responsiveness
DE69937558T2 (de) 1998-06-03 2008-03-06 Scott Laboratories, Inc., Lubbock Gerät zur linderung von schmerz bei bewusstsein und angstzuständen im zusammenhang mit medizinischen und chirurgischen eingriffen
AU2005201500B2 (en) 1998-06-03 2007-01-04 Scott Laboratories, Inc. Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
DE19940740A1 (de) 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
US6984207B1 (en) 1999-09-14 2006-01-10 Hoana Medical, Inc. Passive physiological monitoring (P2M) system
CA2324967A1 (en) 2000-11-01 2002-05-01 3816133 Canada Inc. System for monitoring patients with alzheimer's disease or related dementia
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
WO2002004570A2 (en) * 2000-07-07 2002-01-17 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020192287A1 (en) * 2000-11-09 2002-12-19 Mooney Mark T. Extrudable compositions for topical or transdermal drug delivery
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
WO2002089794A1 (en) 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
JP2004532475A (ja) 2001-05-15 2004-10-21 サイコジェニックス・インコーポレーテッド 行動情報工学を監視するシステムおよび方法
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US7666337B2 (en) * 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
PT1443912E (pt) 2001-10-12 2007-11-28 Elan Pharma Int Ltd Composições tendo uma combinação de características de libertação imediata e de libertação controlada
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US7993674B2 (en) 2002-02-13 2011-08-09 Weibel Michael K Drug dose-form and method of manufacture
AU2003282758A1 (en) 2002-10-08 2004-05-04 Allergan, Inc. Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
US20040156894A1 (en) 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
EP1663178A1 (en) 2003-05-28 2006-06-07 MonoSolRX, LLC Films based on poly(ethylene oxide), and drug delivery systems made thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
JP4563393B2 (ja) * 2003-10-24 2010-10-13 アドヒーシブズ・リサーチ・インコーポレイテッド 診断デバイス用崩壊性フィルム
US9248146B2 (en) 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
GB0403808D0 (en) * 2004-02-20 2004-03-24 Bioprogress Technology Ltd Films for use as dosage forms
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
US7972621B2 (en) 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US20060058590A1 (en) 2004-08-24 2006-03-16 Shaw Geoffrey M Method and system for assaying agitation
US20060058700A1 (en) 2004-08-26 2006-03-16 Marro Dominic P Patient sedation monitor
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080214903A1 (en) 2005-02-22 2008-09-04 Tuvi Orbach Methods and Systems for Physiological and Psycho-Physiological Monitoring and Uses Thereof
CA2599937A1 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2007010242A1 (en) 2005-07-18 2007-01-25 Imperial College Innovations Limited Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
US20070106126A1 (en) 2005-09-30 2007-05-10 Mannheimer Paul D Patient monitoring alarm escalation system and method
WO2007041697A2 (en) 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8048449B2 (en) 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
NZ570492A (en) 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
US7630758B2 (en) 2006-06-22 2009-12-08 General Electric Company Separation of natural and drug-induced sleep of a subject
US20080026040A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
CN101516331A (zh) 2006-09-20 2009-08-26 莫诺索尔克斯有限公司 含有抗泡沫调味剂的可食用水溶性膜
US8157730B2 (en) 2006-12-19 2012-04-17 Valencell, Inc. Physiological and environmental monitoring systems and methods
US20080153808A1 (en) 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8568777B2 (en) 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
CA2687085A1 (en) 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
US20090099480A1 (en) 2007-05-24 2009-04-16 Peter Salgo System and method for patient monitoring
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20110269777A1 (en) 2007-08-01 2011-11-03 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
EA021392B1 (ru) 2007-10-11 2015-06-30 Филип Моррис Продактс С.А. Бездымный табачный продукт
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
PE20091084A1 (es) 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
CN101496801A (zh) 2008-02-02 2009-08-05 四川百利药业有限责任公司 右旋美托咪定及其药用盐的用途
DK2252290T3 (en) 2008-02-15 2018-03-05 Bone Therapeutics Sa PHARMACEUTICAL COMPOSITION FOR USE FOR TREATMENT AND / OR PREVENTION OF OSTEOARTICULAR DISEASES
CN102036655B (zh) 2008-02-28 2013-11-20 R·P·舍勒科技有限责任公司 使多晶型现象最小化的方法
US20190216389A1 (en) 2008-04-07 2019-07-18 Christopher Scheib Method and system for analyzing a series of electroencephalogram (eeg) signals during altered brain states
US20090275853A1 (en) 2008-04-30 2009-11-05 The General Electric Company Method and apparatus for monitoring physiological state of a subject
US8882684B2 (en) 2008-05-12 2014-11-11 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
EP2340254B8 (en) 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US8470546B2 (en) 2008-11-25 2013-06-25 Albert Einstein College Of Medicine Of Yeshiva University Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus-Noradrenergic system
US20100196286A1 (en) 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8282954B2 (en) 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
TR200903014A1 (tr) 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US20130072532A1 (en) 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US20110245633A1 (en) 2010-03-04 2011-10-06 Neumitra LLC Devices and methods for treating psychological disorders
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CA2796280A1 (en) 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Topical treatments for pain
US9572773B2 (en) 2010-04-26 2017-02-21 Novartis A.G. Layered drug delivery device
US20110290694A1 (en) 2010-05-27 2011-12-01 Monosol Rx, Llc Oral film dosage form having indicia thereon
CA2807271C (en) * 2010-06-10 2018-07-31 Midatech Limited Nanoparticle film delivery systems
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
EP2605698B1 (en) 2010-08-17 2020-04-15 University of Florida Research Foundation, Inc. Central site photoplethysmography, medication administration, and safety
AU2011305600B2 (en) 2010-09-23 2016-05-19 Aquestive Therapeutics, Inc. Method and system for forming a pharmaceutical product directly onto a packaging surface
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit
HUE049349T2 (hu) 2010-12-16 2020-09-28 Sunovion Pharmaceuticals Inc Szublingvális filmek
EP2670368A4 (en) * 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
US20140163080A1 (en) 2011-02-03 2014-06-12 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8703697B2 (en) 2011-06-24 2014-04-22 Luc QUINTIN Method for treating early severe diffuse acute respiratory distress syndrome
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
AU2012352528B9 (en) * 2011-12-11 2017-11-02 Baudax Bio, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
JP5921928B2 (ja) 2012-03-28 2016-05-24 テルモ株式会社 既希釈デクスメデトミジン製剤
CN102657635B (zh) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
US10130766B1 (en) 2012-08-08 2018-11-20 Neurowave Systems Inc. Intelligent pharmaceutical delivery system with automatic shutoff and method of using
US20140180160A1 (en) 2012-10-12 2014-06-26 Emery N. Brown System and method for monitoring and controlling a state of a patient during and after administration of anesthetic compound
PL2719376T3 (pl) 2012-10-12 2015-08-31 Omya Int Ag Gastroretencyjny preparat leku oraz sposoby dostarczania i sposób jego wytwarzania z użyciem funkcjonalizowanego węglanu wapnia
US10780079B2 (en) 2012-10-15 2020-09-22 Orion Corporation Veterinary method of alleviating noise aversion
GB2510321B (en) 2012-11-12 2018-01-31 Biosurgical S L Agitation apparatus
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
EP2964270A4 (en) 2013-02-21 2017-03-22 University Of Rochester Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon
US9346601B2 (en) 2013-03-15 2016-05-24 Monosol Rx, Llc Reduction in stress cracking of films
US20140261990A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Multi-layer films having uniform content
US20140328898A1 (en) 2013-03-15 2014-11-06 Children's National Medical Center Nano-Liposomal Formulations and Methods of Use
US9303918B2 (en) 2013-03-15 2016-04-05 Monosol Rx, Llc Process for drying a wet film with control of loss on drying
US9441142B2 (en) 2013-03-22 2016-09-13 Adhesives Research, Inc. Hydrophilic adhesives and tapes and devices containing the same
US20140316217A1 (en) 2013-04-23 2014-10-23 Patrick L. Purdon System and method for monitoring anesthesia and sedation using measures of brain coherence and synchrony
WO2014176436A1 (en) 2013-04-24 2014-10-30 The General Hospital Corporation System and method for estimating high time-frequency resolution eeg spectrograms to monitor patient state
US20140323898A1 (en) 2013-04-24 2014-10-30 Patrick L. Purdon System and Method for Monitoring Level of Dexmedatomidine-Induced Sedation
CN103284945A (zh) 2013-06-03 2013-09-11 四川百利药业有限责任公司 一种预充式盐酸右美托咪定注射液的制备方法
CA2913731C (en) 2013-06-04 2021-05-25 Monosol Llc Water-soluble film sealing solutions, related methods, and related articles
US10314503B2 (en) 2013-06-27 2019-06-11 The General Hospital Corporation Systems and methods for tracking non-stationary spectral structure and dynamics in physiological data
WO2014210527A1 (en) 2013-06-28 2014-12-31 The General Hospital Corporation System and method to infer brain state during burst suppression
US10602978B2 (en) 2013-09-13 2020-03-31 The General Hospital Corporation Systems and methods for improved brain monitoring during general anesthesia and sedation
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
EP3054934B1 (en) 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
CN105764495A (zh) 2013-10-07 2016-07-13 帝国制药美国公司 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
WO2015069778A1 (en) 2013-11-05 2015-05-14 The General Hospital Corporation System and method for determining neural states from physiological measurements
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
WO2015093503A1 (ja) 2013-12-18 2015-06-25 丸石製薬株式会社 含水型貼付剤
US20170274174A1 (en) 2014-08-22 2017-09-28 The General Hospital Corporation System and method for administering, monitoring and controlling biomimetic sleep
US20170273611A1 (en) 2014-08-22 2017-09-28 The General Hospital Corporation Systems and methods for discovery and characterization of neuroactive drugs
US20170231556A1 (en) 2014-08-22 2017-08-17 The General Hospital Corporation Systems and methods for predicting arousal to consciousness during general anesthesia and sedation
CN104161760A (zh) 2014-09-01 2014-11-26 西北农林科技大学 一种貉用复合麻醉剂及其制备方法和应用
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
WO2016061554A1 (en) 2014-10-16 2016-04-21 Bioxcel Corporation Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
FI127534B (en) 2014-11-10 2018-08-31 Vetcare Oy Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
JP2016154598A (ja) 2015-02-23 2016-09-01 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
CN104784174A (zh) 2015-03-06 2015-07-22 北京大学第一医院 右美托咪定的药物新用途
CN107683140A (zh) 2015-04-10 2018-02-09 特丽珂生物医学股份有限公司 用于控制出血和用于促进治愈的生物粘附性脱乙酰壳多糖凝胶，其减少疤痕而不模糊或干扰术野的获得
CN106038538A (zh) 2015-04-17 2016-10-26 江苏恒瑞医药股份有限公司 一种右美托咪定的预混合制剂
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20160374588A1 (en) 2015-06-24 2016-12-29 Microsoft Technology Licensing, Llc Monitoring hydration based on galvanic skin response
CN105168122B (zh) 2015-09-24 2018-11-27 辰欣药业股份有限公司 一种盐酸右美托咪定注射液及其制备工艺
US20170128421A1 (en) 2015-11-11 2017-05-11 Siva Prasad Reddy Sura Premix formulation for parenteral use and packaging thereof
US10632043B2 (en) 2015-11-11 2020-04-28 Aurobindo Pharma Ltd Premix formulation for parenteral use and packaging thereof
US20190290474A1 (en) 2016-01-04 2019-09-26 Jurox Pty Ltd Drug release device and use
CN105534891A (zh) 2016-01-18 2016-05-04 南京正科医药股份有限公司 一种盐酸右美托咪定注射液
US9949934B1 (en) 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
CN107412152B (zh) 2016-05-24 2020-12-04 海南合瑞制药股份有限公司 一种盐酸右美托咪定注射液组合物
WO2017213977A1 (en) 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
CN105997955B (zh) 2016-06-28 2017-09-12 力品药业（厦门）有限公司 一种帕洛诺司琼口腔膜剂及其制备方法
RU2635532C1 (ru) 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
CN110114119B (zh) * 2016-10-12 2022-05-31 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
MX384337B (es) 2016-10-13 2025-03-14 Catalent Uk Swindon Zydis Ltd Composiciones farmacéuticas liofilizadas para suministro vaginal.
US11517533B2 (en) 2016-10-25 2022-12-06 Catalent U.K. Swindon Zydis Limited Compositions of different densities for fast disintegrating multi-layer tablet
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
WO2018081812A2 (en) 2016-10-31 2018-05-03 Teikoku Pharma Usa, Inc. Methods of managing pain using dexmedetomidine transdermal delivery devices
CN106727524A (zh) 2016-11-08 2017-05-31 叶茂 一种药物组合物及其应用
CN106727443A (zh) 2016-12-08 2017-05-31 武汉大学 一种小儿麻醉术前镇静的隐形鼻贴制剂及其制备方法
CN106539778A (zh) 2016-12-08 2017-03-29 武汉大学 一种小儿麻醉术前含服口腔泡腾片及其制备方法
AU2017378203B2 (en) 2016-12-13 2022-12-08 Orion Corporation Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs
WO2018116202A1 (en) 2016-12-20 2018-06-28 Azista Industries Pvt Ltd Stabilized mouth freshener strips
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
US11554106B2 (en) 2017-03-07 2023-01-17 Marc Childs Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin
CN107412204A (zh) 2017-04-24 2017-12-01 重庆医科大学附属儿童医院 一种用于麻醉的干粉吸入剂及其制备方法
CN107693485A (zh) 2017-04-24 2018-02-16 重庆医科大学附属儿童医院 一种用于麻醉的滴鼻液及其制备方法
CN107137399A (zh) 2017-04-24 2017-09-08 徐颖 一种用于麻醉的舌下片及其制备方法
CN107028880A (zh) 2017-06-09 2017-08-11 安徽赛诺制药有限公司 一种盐酸右美托咪定注射液的生产工艺
US20200368352A1 (en) 2017-08-15 2020-11-26 The Board Of Trustees Of The Leland Stanford Junior University Polymeric perfluorocarbon nanoemulsions for ultrasonic drug uncaging
AU2018319592B2 (en) 2017-08-20 2024-06-27 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
WO2019070929A1 (en) 2017-10-04 2019-04-11 The General Hospital Corporation SYSTEMS AND METHODS FOR MONITORING A SUBJECT UNDER THE INFLUENCE OF MEDICAMENTS
US20190216345A1 (en) 2017-10-18 2019-07-18 Christoper Scheib Method and system for monitoring and displaying physiological conditions
US11147459B2 (en) 2018-01-05 2021-10-19 CareBand Inc. Wearable electronic device and system for tracking location and identifying changes in salient indicators of patient health
US11406316B2 (en) 2018-02-14 2022-08-09 Cerenion Oy Apparatus and method for electroencephalographic measurement
CA3089172A1 (en) 2018-03-08 2019-09-12 Catalent U.K. Swindon Zydis Limited Process to reduce endotoxin in gelatin
KR20190109310A (ko) 2018-03-15 2019-09-25 주식회사 바이오홀딩스 레반을 함유하는 염증성 질환 치료용 경비투여형 스프레이 제제
CN108498469A (zh) 2018-05-30 2018-09-07 宁波蒙曼生物科技有限公司 盐酸右美托咪定冻干粉及其制备方法
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
US20210267944A1 (en) 2018-06-27 2021-09-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CN110893186A (zh) 2018-09-12 2020-03-20 宜昌人福药业有限责任公司 一种药物组合物及其制备方法和用途
JP2019048091A (ja) 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
KR102183744B1 (ko) 2018-11-26 2020-11-27 연세대학교 산학협력단 섬망 발병 위험도의 예측 방법 및 이를 이용한 디바이스
CN109620802A (zh) 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN111481506B (zh) 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
US10900762B2 (en) 2019-02-21 2021-01-26 Aob Products Company Ammunition press and components thereof
WO2020259440A1 (zh) 2019-06-28 2020-12-30 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN112138250B (zh) 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
AU2020351171A1 (en) 2019-09-18 2022-05-05 Bioxcel Therapeutics, Inc. Systems and methods for detection and prevention of emergence of agitation
AU2021218422A1 (en) 2020-02-14 2022-09-22 Bioxcel Therapeutics, Inc. Systems and methods for detection and prevention of emergence of agitation
TW202228682A (zh) 2020-10-08 2022-08-01 美商百歐克斯賽爾治療公司 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
TW202241416A (zh) 2021-01-04 2022-11-01 美商百歐克斯賽爾治療公司 右美托咪啶（ｄｅｘｍｅｄｅｔｏｍｉｄｉｎｅ）治療方案
CA3208828A1 (en) 2021-02-26 2022-09-01 Dinesh Kumar DHULL Methods and compositions for treating agitation

Also Published As

Publication number Publication date
US11517524B2 (en) 2022-12-06
CN112888431B (zh) 2022-06-03
AU2019295699A1 (en) 2021-01-28
SG11202012772XA (en) 2021-01-28
ES3004544T3 (en) 2025-03-12
EP4523752A3 (en) 2025-05-14
CN114983980A (zh) 2022-09-02
CN112888431A (zh) 2021-06-01
CN114983979A (zh) 2022-09-02
US20220142918A1 (en) 2022-05-12
JP7488201B2 (ja) 2024-05-21
JP2021529756A (ja) 2021-11-04
TW202019388A (zh) 2020-06-01
CA3103431A1 (en) 2020-01-02
US10792246B2 (en) 2020-10-06
US11497711B2 (en) 2022-11-15
US20230390190A1 (en) 2023-12-07
JP2024112848A (ja) 2024-08-21
BR112020026672A2 (pt) 2021-03-30
US11806429B2 (en) 2023-11-07
KR102824967B1 (ko) 2025-06-25
EP3813802A4 (en) 2022-06-08
US11559484B2 (en) 2023-01-24
CN115154440A (zh) 2022-10-11
US20200000717A1 (en) 2020-01-02
EP3813802B1 (en) 2024-10-23
IL279713A (en) 2021-03-01
IL279713B2 (en) 2025-01-01
AU2025202163A1 (en) 2025-04-10
EP4523752A2 (en) 2025-03-19
US20220160629A1 (en) 2022-05-26
US20210077388A1 (en) 2021-03-18
WO2020006092A1 (en) 2020-01-02
PL3813802T3 (pl) 2025-04-22
US20230381099A1 (en) 2023-11-30
EP3813802A1 (en) 2021-05-05
IL279713B1 (en) 2024-09-01
US20220110864A1 (en) 2022-04-14
US20230140624A1 (en) 2023-05-04
PT3813802T (pt) 2025-01-15
KR20210028192A (ko) 2021-03-11
US11478422B2 (en) 2022-10-25
US20200345635A1 (en) 2020-11-05
CN114983981A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
EA202190115A1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения
MX2021002322A (es) Nuevos metodos.
MX2024010140A (es) Nuevos metodos.
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12020550341A1 (en) Niraparib formulations
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MY197171A (en) Compounds and methods for the treatment of parasitic diseases
PH12017502249A1 (en) Tofacitinib orally disintegrating tablets
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2018007440A (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
MX2020002725A (es) Nueva formulacion de acido gamma-aminobutirico.
EA201800091A1 (ru) Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения
PH12016502527B1 (en) Stabilized desmopressin
CY1120282T1 (el) Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση